{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:41Z","timestamp":1790352521793,"version":"4.1.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"31","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.2217\/fon-2022-0666","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:19:44Z","timestamp":1662477584000},"page":"3481-3492","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["EPIK-O\/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-1479","authenticated-orcid":false,"given":"Panagiotis A","family":"Konstantinopoulos","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez-Martin","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra & Program in Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, 31008, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Melo","family":"Cruz","sequence":"additional","affiliation":[{"name":"N\u00facleo de Pesquisa e Ensino da Rede S\u00e3o Camilo, S\u00e3o Paulo, 04014-002, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-795X","authenticated-orcid":false,"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Prince of Wales Hospital & Prince of Wales Clinical School, University of New South Wales, Sydney, 2031, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-1680","authenticated-orcid":false,"given":"Rosalind","family":"Glasspool","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre & University of Glasgow, Glasgow, G12, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS & Catholic University of Sacred Heart, Rome, 00168, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-9981","authenticated-orcid":false,"given":"Christian","family":"Marth","sequence":"additional","affiliation":[{"name":"Medizinische Universit\u00e4t Innsbruck, Innsbruck, 6020, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ85012, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-9436","authenticated-orcid":false,"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University, Seoul, 08826, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patsy","family":"Hinson","sequence":"additional","affiliation":[{"name":"Ovarian Cancer Research Alliance (OCRA), New York, NY10122, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ajipa","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pretre","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-6992","authenticated-orcid":false,"given":"Ursula A","family":"Matulonis","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0084"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.04.013"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072239"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4019"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62146-7"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00933-8"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051315"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0055-6"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz192"},{"key":"e_1_3_6_23_1","unstructured":"Lynparza\u00ae (olaparib) [Prescribing Information]. AstraZeneca Pharmaceuticals LP Wilmington DE. https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/00997c3f-5912-486f-a7db-930b4639cd51\/00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909707"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.12.002"},{"issue":"15","key":"e_1_3_6_28_1","article-title":"Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib\/placebo maintenance in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"39","author":"Pautier P","year":"2021","unstructured":"Pautier P , HarterP, PisanoCet al. Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib\/placebo maintenance in the phase III PAOLA-1\/ENGOT-ov25 trial. J. Clin. Oncol.39(Suppl. 15), Abstract 5514 (2021).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw663"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.03.005"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.195"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0336"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00194"},{"key":"e_1_3_6_34_1","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines)","author":"National Comprehensive Cancer Network","year":"2022","unstructured":"National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN guidelines). Ovarian Cancer (version 1.2022) (2022). www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf","journal-title":"Ovarian Cancer"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw133"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70214-5"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70240-7"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"},{"key":"e_1_3_6_39_1","unstructured":"Piqray\u00ae (alpelisib) [Prescribing Information]. Novartis Pharmaceuticals Corporation East Hanover NJ. www.novartis.com\/us-en\/sites\/novartis_us\/files\/piqray.pdf"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"issue":"13","key":"e_1_3_6_41_1","article-title":"Determination of the PI3K\u03b1 selective inhibitor alpelisib mechanism of action and efficacy in ER+\/ PIK3CA mutant breast cancer preclinical models","volume":"78","author":"Fritsch C","year":"2018","unstructured":"Fritsch C , PfisterE, EbelNet al. Determination of the PI3K\u03b1 selective inhibitor alpelisib mechanism of action and efficacy in ER+\/ PIK3CA mutant breast cancer preclinical models. Cancer Res.78(Suppl. 13), Abstract 3934 (2018).","journal-title":"Cancer Res."},{"issue":"3","key":"e_1_3_6_42_1","first-page":"573","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer","volume":"4","author":"Rinne N","year":"2021","unstructured":"Rinne N , ChristieEL, ArdashevaAet al. Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist.4(3), 573\u2013595 (2021).","journal-title":"Cancer Drug Resist."},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.1360"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0348"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0336"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1522223113"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911217"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1237"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30905-7"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.01.034"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0782"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:49Z","timestamp":1719125029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":51,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.2217\/fon-2022-0666"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0666","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}